NOVEL AMYLOID-β OLIGOMER-SPECIFIC EPITOPES: A HYPOTHESIS DRIVEN APPROACH TO ALZHEIMER'S IMMUNOTHERAPEUTICS
Judith M. Silverman,Ebrima Gibbs,Jing Wang,Xubiao Peng,Steve Plotkin,Neil R. Cashman
DOI: https://doi.org/10.1016/j.jalz.2016.07.145
2016-01-01
Alzheimer s & Dementia
Abstract:Alzheimer’s disease (AD) Aβ immunotherapeutics in humans have been hampered by negative side-effects including ARIA-E and cerebral microhemorrhage1, mediated by antibody binding to non-toxic fibrils and/or monomers2. Recent advances have demonstrated the fundamental role of amyloid-β oligomers (AβO) in disease onset3, synaptotoxicity4 and progression5,6. Together with promising results from clinical trials targeting aggregated Aβ7, these data suggest that by targeting AβOs, a blockade of cognitive decline in humans is possible. We used computational epitope discovery methods to identify immunologic targets on toxic and propagating AβO, that are necessarily absent on Aβ monomers and plaques. Proprietary algorithms have computationally predicted five AβO-specific epitopes. The epitopes were synthesized and conjugated to immunogens, validated for sequence and structure, and used to produce monoclonal antibodies. Surface Plasmon Resonance (SPR) will screen clones against structured and unstructured epitopes and synthetic AβOs, monomers and fibrils. Further validation will include screening antibodies (SPR, immunoprecipitation, immunoblotting) against brain extract and CSF from AD patients and age matched human controls. Antibodies with cross reactivity to monomers and/or fibrils and plaques, determined by immunohistochemistry in brain tissue, will be rejected. Oligomer specific antibodies with no off-target binding will be evaluated in vitrofor the ability to neutralize neurotoxicity and propagation. The target profile of the AβO-specific antibodies is murine monoclonal antibodies that react with synthetic oligomers over monomers with an affinity of least 1/100, or react with native oligomers in brain and CSF with low affinity binding to monomers, and do not react with plaques. The computational epitope discovery approach may produce multiple AβO-specific antibodies. If successful, the approach may be applicable to other proteins and protein misfolding diseases. Acknowledgements: ProMIS Neurosciences, the exclusive licenser of the AβO epitope technology, has supported this work through a sponsored research agreement with UBC. 1 Panza, F. et al. Curr Opin Psychi(2014). 2 Winblad, B. et al. Lancet Neurol(2016). 3 Lesne, S. E. et al. Brain(2013). 4 Ferreira, S. T. et al. Front in Cell Neurosci(2015). 5 Jaunmuktane, Z. et al. Nature(2015). 6 Ye, L. et al. Brain Pathol(2015). 7 Patel, K. R. Manag Care (2015).